- Home
- BHRB vs NUVB Comparison
BHRB vs NUVB Comparison
Compare BHRB & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHRB
- NUVB
- Stock Information
- Founded
- BHRB 1852
- NUVB 2018
- Country
- BHRB United States
- NUVB United States
- Employees
- BHRB N/A
- NUVB N/A
- Industry
- BHRB Major Banks
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- BHRB Finance
- NUVB Health Care
- Exchange
- BHRB Nasdaq
- NUVB Nasdaq
- Market Cap
- BHRB 843.3M
- NUVB 679.9M
- IPO Year
- BHRB N/A
- NUVB N/A
- Fundamental
- Price
- BHRB $63.02
- NUVB $2.05
- Analyst Decision
- BHRB Strong Buy
- NUVB Strong Buy
- Analyst Count
- BHRB 2
- NUVB 6
- Target Price
- BHRB $73.00
- NUVB $7.83
- AVG Volume (30 Days)
- BHRB 73.1K
- NUVB 8.9M
- Earning Date
- BHRB 07-25-2025
- NUVB 08-04-2025
- Dividend Yield
- BHRB 3.49%
- NUVB N/A
- EPS Growth
- BHRB 46.75
- NUVB N/A
- EPS
- BHRB 3.98
- NUVB N/A
- Revenue
- BHRB $288,679,000.00
- NUVB $10,957,000.00
- Revenue This Year
- BHRB $51.95
- NUVB $101.21
- Revenue Next Year
- BHRB $4.56
- NUVB $410.28
- P/E Ratio
- BHRB $15.84
- NUVB N/A
- Revenue Growth
- BHRB 168.50
- NUVB N/A
- 52 Week Low
- BHRB $47.28
- NUVB $1.54
- 52 Week High
- BHRB $75.32
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- BHRB 72.05
- NUVB 49.73
- Support Level
- BHRB $59.19
- NUVB $1.87
- Resistance Level
- BHRB $59.45
- NUVB $2.10
- Average True Range (ATR)
- BHRB 1.63
- NUVB 0.18
- MACD
- BHRB 0.47
- NUVB 0.00
- Stochastic Oscillator
- BHRB 97.19
- NUVB 71.97
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).